(ii) Indications for use. For the treatment and control of large strongyles (adult) (*Strongylus vulgaris*, *S. edentatus*, *Triodontophorus* spp.), small strongyles (adult and fourth stage larvae) (*Cyathostomum* spp., *Cylicoclypus* spp., *Clycicostephanus* spp.), pinworms (adult and fourth-stage larvae) (*Oxyuris equi*), large roundworms (adult) (*Parascaris equorum*), hairworms (adult) (*Trichostrongyulus axei*), large mouth stomach worms (adult) (*Habronema muscae*), stomach bots (mature larvae) (*Cyathostomum viviparus*), and fourth-stage larvae) (*Oxyuris equi*), small strongyles (adults and fourth-stage larvae) (*Oesophagostomum* spp.), and threadworms (microfilariae) (*Onchocerca* spp.), and stomach hots (*Gastrophilus* spp.).

(iii) Limitations. Not for use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle—(i) Amount. 200 μg/kg of body weight by subcutaneous injection.

(ii) Indications for use.—(A) For the treatment and control of gastro-intestinal nematodes (adults and fourth-stage larvae) (*Haemonchus placei*, *Ostertagia ostertagi* (including inhibited larvae), *O. lyrata*, *T. axei*, *T. colubriformis*, *Cooperia oncophora*, *C. punctata*, *C. pectinata*, *Oesophagostomum radiatum*, *Nematodirus helvetianus* (adults only), *N. spathiger*; *Bunostomum phlebotomum* (adults only), *N. ransomi*; *Metastrongylus* spp.; *Haemonchus placei*, *Haemonchus bovis* (adults only), *O. lineatum*; *Haemonchus suis*; *Hyostrongylus ransomi* (adults only)); somatic roundworm larvae (threadworm, *S. ransomi* (somatic larvae)); lungworms (*Oesophagastrum radiatum* spp. (adults only)); lice (*Linognathus vituli*, *Haematopinus eurysternus*, *Solenopotes capillatus*); mites (scabies) (*Psoroptes ovis* (syn. *P. communis var. bovis*), *Sarcoptes scabiei var. bovis*).

(B) For control of infections of *D. vivipar us* for 28 days after treatment, and *O. ostertagi* for 21 days after treatment, and *H. placei*, *T. axei*, *C. punctata*, *C. oncophora*, and *O. radiatum* for 14 days after treatment.

(C) For control of infections and to protect from reinfection with *D. vivipar us* and *O. radiatum* for 28 days after treatment; *O. ostertagi*, *T. axei*, and *C. punctata* for 21 days after treatment; *H. placei* and *C. oncophora* for 14 days after treatment.

(iii) Limitations. Do not treat cattle within 35 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

(3) Swine—(i) Amount. 300 μg/kg of body weight by subcutaneous injection.


(iii) Limitations. Do not treat swine within 18 days of slaughter.

(4) American bison—(i) Amount. 200 μg/kg of body weight by subcutaneous injection.

(ii) Indications for use. For the treatment and control of grubs (*H. bovis*).

(iii) Limitations. Do not slaughter within 56 days of last treatment.

(5) Reindeer—(i) Amount. 200 μg/kg of body weight by subcutaneous injection.

(ii) Indications for use. For the treatment and control of warbles (*Oedemagena tarandi*).

(iii) Limitations. Do not treat reindeer within 56 days of slaughter.

(6) Ranch-raised foxes—(i) Amount. 200 μg/kg of body weight by subcutaneous injection. Repeat in 3 weeks.

(ii) Indications for use. For treatment and control of ear mites (*Otodectes cynotis*).


§ 522.1193 Ivermectin and clorsulon.

(a) Specifications. Each milliliter (mL) of solution contains 10 milligrams (mg) (1 percent) ivermectin and 100 mg (10 percent) clorsulon.

(b) Sponsors. See Nos. 050604 and 055529 in §510.600(c) of this chapter for use as in paragraph (e) of this section.

(c) Related tolerances. See §§556.163 and 556.344 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(e) Conditions of use in cattle—(1) Amount. Administer 1 mL (10 mg ivermectin and 100 mg clorsulon) per 50 kilograms (110 pounds) by subcutaneous injection.
(2) Indications for use. For the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and fourth-stage larvae) (Dictyocaulus viviparus); liver flukes (adults only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. bovis), Sarcoptes scabiei var. bovis); and for control of infections of D. viviparus and O. radiatum for 28 days after treatment; O. ostertagi, T. axei, and C. punctata for 21 days after treatment; and H. placei and C. oncophora for 14 days after treatment.

(3) Limitations. For subcutaneous use only. Not for intravenous or intramuscular use. Do not treat cattle within 49 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. Do not use in other animal species because severe adverse reactions, including fatalities in dogs, may result. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

§ 522.1204 Kanamycin sulfate injection.

(a) Specifications. Each milliliter contains kanamycin hydrochloride equivalent to 100 milligrams (mg) kanamycin base activity.

(b) Sponsor. See Nos. 000010, 000074, 000856, 059130, 061690, 026637, and 064847 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Cats—(i) Amount. 5 to 15 mg/pound body weight intramuscularly, depending on the effect desired.

(ii) Indications for use. For restraint or as the sole anesthetic agent in diagnostic or minor, brief surgical procedures that do not require skeletal muscle relaxation.

(2) Subhuman primates—(i) Amount. 3 to 15 mg/kilogram body weight intramuscularly, depending upon the species, general condition, and age of the subject.

(ii) Indications for use. For restraint.

§ 522.1222b Ketamine hydrochloride with promazine hydrochloride and aminopentamide hydrogen sulfate injection.

(a) Chemical name. Ketamine hydrochloride, (±)-2-(o-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride, with promazine hydrochloride, 10-[3-(dimethylamino) propyl] phenothiazine monohydrochloride, and aminopentamide hydrogen sulfate.

(b) Sponsor. The drug is a sterile aqueous solution and each milliliter contains: Ketamine hydrochloride equivalent to 100 milligrams ketamine base activity, 7.5 milligrams of promazine hydrochloride, and 0.0625 milligram of aminopentamide hydrogen sulfate, with 1:10,000 benzethonium chloride.